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ABSTRACT
Background: Cilostazol overcomes high on-treatment
platelet reactivity (HTPR) and reduces adverse
cardiovascular (CV) outcomes after percutaneous
coronary intervention (PCI). However, the role for triple
antiplatelet therapy (TAPT) with cilostazol in addition to
aspirin and clopidogrel after PCI is not well defined.
Methods: We conducted a MEDLINE/EMBASE/
CENTRAL search for randomised trials, until May 2014,
evaluating TAPT compared with dual antiplatelet
therapy (DAPT) of aspirin and clopidogrel alone in
patients undergoing PCI and reporting platelet
reactivity and/or CV outcomes. The primary platelet
reactivity outcome was differences in platelet reactivity
unit (PRU) with secondary outcomes of %platelet
inhibition and rate of HTPR. The primary CV outcome
was major adverse cardiovascular events (MACE), with
secondary outcomes of death, cardiovascular death,
myocardial infarction, stent thrombosis (ST), target
lesion revascularisation (TLR) and target vessel
revascularisation (TVR) as well as safety outcomes of
bleeding and drug discontinuations.
Results: In 17 trials that evaluated platelet reactivity
outcomes, the mean PRU value was 47.73 units lower
with TAPT versus DAPT (95% CI −61.41 to −34.04,
p<0.0001; mean PRU 182.90 vs 232.65). TAPT also
increased platelet inhibition by 12.71% (95% CI 10.76
to 14.67, p<0.0001), and led to a 60% reduction in the
risk of HTPR (relative risk=0.40; 95% CI 0.30 to 0.53)
compared with DAPT. Moreover, among the 34 trials
that evaluated CV outcomes, TAPT reduced the risk of
MACE (incident rate ratio (IRR)=0.68; 95% CI 0.60 to
0.78), TLR (IRR=0.57; 95% CI 0.44 to 0.73), TVR
(IRR=0.69; 95% CI 0.59 to 0.81) and ST (IRR=0.63;
95% CI 0.40 to 0.98) with no difference for other
outcomes including bleeding, even in trials using drug-
eluting stents. Drug discontinuation due to adverse
effects was, however, higher with TAPT vs DAPT
(IRR=1.59; 95% CI 1.32 to 1.91).
Conclusions: In patients undergoing PCI, addition of
cilostazol to DAPT results in decreased platelet
reactivity and a significant reduction in CV outcomes
including ST, even in the drug-eluting stent era.
INTRODUCTION
Dual antiplatelet therapy (DAPT) with aspirin
and an ADP receptor inhibitor is the standard
of care for patients undergoing percutaneous
coronary intervention (PCI). However, there
is signiﬁcant interindividual variability in the
extent of platelet inhibition achieved with clo-
pidogrel.
1–3 Several studies have shown a cor-
relation between high levels of on-treatment
platelet reactivity (HTPR) and adverse cardio-
vascular outcomes, such that patients with
HTPR (also called clopidogrel resistance)
have a threefold to ﬁvefold increased risk for
recurrent ischaemic events.
45Cilostazol, a
phosphodiesterase III inhibitor, exhibits its
antiplatelet effects via inhibition of the con-
version of cyclic AMP (cAMP) to 5’-AMP
KEY MESSAGES
What is already known about this subject?
▸ Cilostazol, a phosphodiesterase III inhibitor,
exhibits antiplatelet effect and inhibits neointimal
hyperplasia and smooth muscle proliferation.
However, its role in addition to dual antiplatelet
therapy (DAPT) of aspirin and clopidogrel in
patients undergoing percutaneous coronary
intervention (PCI) is not well defined.
What does this study add?
▸ In patients undergoing PCI, addition of cilostazol
to DAPT results in decreased platelet reactivity
and a significant reduction in cardiovascular out-
comes including stent thrombosis, even in the
drug-eluting stent era.
How might this impact on clinical practice?
▸ The current study provides evidence to support
use of cilostazol as an attractive and strong
competitor for newer antiplatelet regimens and
should be evaluated in future trials in patients
undergoing PCI.
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Coronary artery diseasecausing a subsequent increase in cAMP within platelets,
and has been shown to augment platelet inhibition when
it is added to aspirin and clopidogrel as part of a triple
therapy regimen.
67In addition, cilostazol inhibits neoin-
timal hyperplasia and smooth muscle proliferation, and
has the potential to reduce the risk of restenosis after cor-
onary stent implantation.
8–11 Despite these pharmaco-
logic effects, clinical results from observational and small
randomised trials have not shown a consistent clinical
beneﬁt.
Our objective was to evaluate whether triple antiplate-
let therapy (TAPT) with cilostazol (in addition to aspirin
and clopidogrel) decreases platelet reactivity and
reduces adverse cardiovascular (CV) outcomes when
compared with a dual antiplatelet (DAPT) regimen of
aspirin and clopidogrel alone.
METHODS
Eligibility criteria
We conducted a MEDLINE, EMBASE and CENTRAL
search using the MeSH terms ‘cilostazol’ and ‘rando-
mised clinical trial’. We limited our search to trials
involving human subjects through May 2014. The search
terms were broad with no language restrictions imposed.
We checked the reference lists of review articles and
prior meta-analyses to assess for additional eligible
studies. Corresponding authors of studies were con-
tacted for further information if relevant data were not
reported. Trials in abstract format without a manuscript
published were also included in the analysis.
To be included for analysis, eligible trials had to fulﬁl
the following criteria: (1) randomised clinical trials of
TAPT (aspirin, clopidogrel and cilostazol) in compari-
son to DAPT (aspirin and clopidogrel); (2) enrolment
of patients undergoing PCI with drug-eluting or bare
metal stents and (3) follow-up of at least 2 weeks for
trials reporting platelet reactivity outcomes and at least
1 month for trials reporting cardiovascular outcomes.
Selection and quality assessment
Three authors (AS, BT and SB) independently reviewed
trial eligibility and quality. Disagreements were resolved
by consensus. Risk of bias was assessed using criteria
recommended by the Cochrane Collaboration, speciﬁc-
ally evaluating sequence generation of allocation; alloca-
tion concealment; blinding of participants, staff and
outcome assessors; incomplete outcome data; selective
outcome reporting; and other sources of bias.
12 Trials
with high or unclear risk of bias for the ﬁrst three cri-
teria were considered as high bias risk trials and the rest
as low bias risk trials.
Data extraction and synthesis
The primary platelet reactivity outcome was differences
in platelet reactivity unit (PRU) after treatment in TAPT
versus DAPT groups. Secondary outcomes were percent
platelet inhibition and rate of HTPR. We used a cut-off
of PRU >235 as the threshold for identifying patients
with HTPR who may be at high risk for ischaemic or
thrombotic events following PCI, as has been recom-
mended by a recent consensus document.
13 Of note,
deﬁnition of HTPR differed by study.
Our primary CV outcome was major adverse cardiovas-
cular events (MACE), deﬁned as death, myocardial
infarction (MI) or target lesion revascularisation (TLR).
We evaluated secondary CV outcomes of death, cardio-
vascular death, MI, stent thrombosis, TLR and target
vessel revascularisation (TVR). Safety outcomes of major
bleeding, minor bleeding, any (major or minor) bleed-
ing and drug discontinuation due to adverse effects
were also evaluated. The deﬁnitions of bleeding varied
between the trials. Given the lack of consistent reporting
of the Academic Research Consortium deﬁnitions of
stent thrombosis from the studies, we used the individual
trial protocol deﬁnitions of stent thrombosis.
Statistical analysis
We performed an intention to treat meta-analysis in line
with recommendations from the Cochrane
Collaboration and the PRISMA Statement
14 15 and used
standard software for statistical analysis (STATA V.9.0,
STATA Corp, Texas, USA). Heterogeneity was assessed
using the I
2 statistic, deﬁned as the proportion of total
variation observed between the trials attributable to dif-
ferences between trials rather than sampling error
(chance), with values <25% considered as low and >75%
as high.
16 The pooled effect for each grouping of trials
was derived from the point estimate for each separate
trial weighted by the inverse of the variance (1/SE
2).
Continuous variable outcomes (PRU, per cent platelet
inhibition) between the groups were compared with
both a ﬁxed effect model using the inverse variance
method and a random effects model using the
DerSimonian and Laird method. For cardiovascular out-
comes, rates were expressed per patient-years to adjust
for the varying duration of follow-up. Results were there-
fore reported as incident rate ratios (IRR) and 95% CIs
with the use of both a ﬁxed effect model using the
method of Mantel and Haenszel and a random effects
model using the method of DerSimonian and Laird,
with the estimate of heterogeneity being taken from the
Mantel-Haenszel model. Publication bias was estimated
using the weighted regression tests of Begg and Egger.
12
For platelet reactivity indices, analyses were stratiﬁed
based on whether standard-dose (75 mg) or high-dose
(150 mg) clopidogrel was used in the DAPT arm. In add-
ition, further sensitivity analyses were performed based
on the cohort enrolled: (1) acute coronary syndrome
(ACS) versus not; and (2) enrolment of patients with
HTPR at baseline versus not. For cardiovascular out-
comes, analyses were stratiﬁed based on stent type—
drug eluting stent (DES) versus Bare metal stent (BMS).
A p value of <0.05 was considered signiﬁcant.
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Study selection
We identiﬁed 41 trials that satisﬁed the inclusion criteria
(ﬁgure 1). Seventeen trials reported platelet reactivity
outcomes of which 10 comparator arms used high dose
(150 mg) of clopidogrel. A total of 34 trials reported CV
outcomes, the majority (25 trials) of which used DES.
Baseline characteristics
The baseline characteristics, inclusion criteria and
quality assessment are summarised in tables 1–4.I n
order to quantify platelet reactivity outcomes, we evalu-
ated 17 trials with 20 comparator arms and 5056
patients. The median follow-up was 30 days and
although the deﬁnition of HTPR was heterogeneous, all
trials used the VerifyNow P2Y12 assay to measure platelet
reactivity. The analysis of cardiovascular outcomes
included 34 trials with 14 119 patients. The mean age of
study participants was between 56.3 and 67.5 years,
37.9% of the patients had diabetes and the majority
(77.6%) underwent PCI with DES.
Primary platelet reactivity outcomes
Primary outcome: differences in PRU
TAPT resulted in a mean PRU reduction of 47.73 (95%
CI −61.41 to −34.04, p<0.0001; mean PRU 182.90 vs
232.65) compared with DAPT (ﬁgure 2A). There was a
larger mean difference between the TAPT and DAPT
groups when the analysis was restricted to a DAPT group
using standard-dose clopidogrel (mean PRU 189.54 vs
255.83) where the PRU value was lower by a mean of 64.10
(95% CI −84.35 to −43.85). Moreover, TAPT was associated
with a lower PRU value even when compared with DAPT
using high-dose clopidogrel (mean difference of 27.17)
(mean PRU 176.27 vs 209.48) (ﬁgure 2A). The results
were similar when stratiﬁed by ACS status (see web appen-
dix ﬁgure A1) or by baseline clopidogrel resistance status
(see web appendix ﬁgure A2). There was moderate-to-high
heterogeneity for the above analysis. However, the hetero-
geneity was reduced in subgroup analysis restricted to com-
parison with high-dose clopidogrel (ﬁgure 2A), in trials
enrolling patients with baseline clopidogrel resistance (see
web appendix ﬁgure A2 and in trials enrolling patients
without ACS (see web appendix ﬁgure A1).
In addition, the mean PRU values on treatment in the
TAPT group in each of the trials were below a PRU of
235, which has been cited in the literature as the sug-
gested threshold for deﬁning HTPR.
13
Secondary outcomes: percent platelet inhibition and high
on-treatment platelet reactivity
TAPT was associated with a 12.71% greater platelet
inhibition compared to DAPT for the overall cohort
Figure 1 Study selection.
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Coronary artery disease(95% CI 10.76 to 14.67, p<0.0001) (ﬁgure 2B). TAPT
was also associated with a greater platelet inhibition in
comparison with DAPT using standard-dose clopidogrel
(14.37% mean greater platelet inhibition) and remained
signiﬁcant even when compared with DAPT using high-
dose clopidogrel (9.07% mean greater platelet inhib-
ition) (ﬁgure 2B). There was moderate heterogeneity
for the above analysis. The results were similar when
stratiﬁed by ACS status (see web appendix ﬁgure A3) or
by baseline clopidogrel resistance status (see web appen-
dix ﬁgure A4).
In addition, TAPTwas associated with a 60% reduction in
the risk of HTPR when compared with DAPT (ﬁgure 2C)
(relative risk=0.40; 95% CI 0.30 to 0.53, p<0.0001). When
stratiﬁed by clopidogrel dose, TAPT was associated with a
50% reduction in risk of HTPR compared to standard-dose
DAPT and a 72% reduction compared to high-dose DAPT
(ﬁgure 2C). Heterogeneity was moderate with no evidence
for signiﬁcant publication bias. The results were similar
when stratiﬁed by ACS status (see web appendix ﬁgure A5)
or by baseline clopidogrel resistance status (see web appen-
dix ﬁgure A6).
Table 1 Baseline characteristics of included trials for platelet reactivity outcomes
Trial Year N Comparison
SD or HD
(DAPT group)
Mean age
(years)
Follow-up
(days)
ACCEL-AMI
29 2009 90 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
Both 62 30
ACCEL-LOADING-ACS
30 2012 218 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
SD 63 30
ACCEL-POLYMORPHISM
31 2010 134 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
HD 63 30
ACCEL-PPI
32 2012 90 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
HD NR 30
ACCEL-RESISTANCE
33 2009 60 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
HD 63 30
CILON-T
34 2011 716 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
SD 64 180
Gao et al
35 2013 428 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
SD 56 365
Guan et al
36 2012 840 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
SD 60 30
HOST-ASSURE
37 2013 1356 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
Both 63 30
Jeong et al
38 2014 275 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
Both NR 30
Jin et al
39 2012 60 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
HD 62 30
Kim et al
40 2011 126 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
HD 62 30
Kim et al
41 2007 60 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
SD 63 30
Kum et al
42 2009 66 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
SD 62 14
Lee et al
43 2010 63 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
Both NR 14
PIANO-2 CKD
44 2011 74 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
Both 53 14
Shim et al
45 2009 379 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
SD 61 14
ACCEL-AMI, adjunctive Cilostazol versus High Maintenance Dose Clopidogrel in patients with AMI; ACCEL-LOADING-ACS, Multicentre
Randomised Trial Evaluating Efficacy of Cilostazol on Platelet Aggregation, Inflammation and Myonecrosis in ACS Patients;
ACCEL-POLYMORPHISM, Cytochrome 2C19 Polymorphism and Response to Adjunctive Cilostazol versus High Maintenance-Dose
Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention; ACCEL-PPI, Pharmacodynamics Effects of Adding Cilostazol versus
Double-dose Clopidogrel in Patients with Acute Myocardial Infarction During Proton Pump Inhibitor Co-administration; ACCEL-RESISTANCE,
Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients with Clopidogrel Resistance; CILON-T, Influence of
Cilostazol-based Triple Antiplatelet Therapy on Ischaemic Complication After Drug-eluting Stent Implantation; HD, high-dose clopidogrel
(150 mg); HOST-ASSURE, Harmonising Optimal Strategy for Treatment of Coronary Artery Stenosis—Safety and Effectiveness of
Drug-Eluting Stents and Antiplatelet Regimen; NR, not reported; PIANO-2 CKD, Platelet Reactivity in Patients with Chronic Kidney Disease
Receiving Adjunctive Cilostazol Compared with a High-Maintenance Dose of Clopidogrel; SD, Standard-dose clopidogrel (75 mg).
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Primary outcome
TAPT was associated with a 32% reduction in the risk of
MACE (IRR=0.68; 95% CI 0.60 to 0.78) when compared
with DAPT for the overall cohort (ﬁgure 3A). This
effect was observed regardless of stent type (Pinteraction
>0.05) such that even in patients undergoing PCI with
DES, TAPT resulted in a 36% reduction in MACE
Table 2 Inclusion criteria and study quality for platelet reactivity outcomes trials
Trial Cohort Definition of HTPR
Platelet
reactivity
assay
Quality of
study*
ACCEL-AMI
29 Patients with ACS undergoing
PCI
5 and 20 μM ADP-induced
maximal platelet aggregation
>50%
VerifyNow
P2Y12; LTA
+++
ACCEL-LOADING-ACS
30 Patients with non-ST-elevation MI
undergoing PCI
NR VerifyNow
P2Y12
±±±
ACCEL-POLYMORPHISM
31 Patients with high post-treatment
platelet reactivity or diabetes
undergoing PCI
5 μM ADP-induced maximal
platelet aggregation >50%
VerifyNow
P2Y12; LTA
+++
ACCEL-PPI
32 Patients with acute MI
undergoing PCI
20 μM ADP-induced
maximal platelet aggregation
>59%
LTA ±±±
ACCEL-RESISTANCE
33 Patients with high on-treatment
platelet reactivity undergoing PCI
5 μM ADP-induced maximal
platelet aggregation >50%
VerifyNow
P2Y12; LTA
++±
CILON-T
34 Patients with angina undergoing
PCI
NR VerifyNow
P2Y12
++±
Gao et al
35 Obese patients undergoing PCI Post-treatment platelet
aggregation absolute
difference 10% or less
LTA ±±±
Guan et al
36 Patients with ACS and high
on-treatment platelet reactivity
undergoing PCI
20 μM ADP-induced
maximal platelet aggregation
>55%
LTA ±±±
HOST-ASSURE
37 All-comer patients undergoing
PCI
NR VerifyNow
P2Y12
±±+
Jeong et al
38 Patients with ACS undergoing
PCI
NR LTA ±±±
Jin et al
39 Patients undergoing PCI % platelet inhibition <20 VerifyNow
P2Y12; LTA
±++
Kim et al
40 Patients with acute MI
undergoing PCI
20 μM ADP-induced
maximal platelet aggregation
>59%
VerifyNow
P2Y12; LTA
++±
Kim et al
41 Patients with ST-elevation MI
undergoing PCI
% platelet inhibition <20 VerifyNow
P2Y12; LTA
±±±
Kum et al
42 Patients undergoing PCI NR VerifyNow
P2Y12
±±±
Lee et al
43 Patients with high on-treatment
platelet reactivity undergoing PCI
% platelet inhibition <20 VerifyNow
P2Y12
+±±
PIANO-2 CKD
44 Patients with renal disease on
haemodialysis undergoing PCI
5 μM ADP-induced maximal
platelet aggregation >50%
VerifyNow
P2Y12; LTA
+++
Shim et al
45 Patients undergoing PCI with
DES
% platelet inhibition <20 VerifyNow
P2Y12
+±±
*Represents risk of bias based on: sequence generation of allocation; allocation concealment and blinding. ‘+’ represents low bias risk,
‘−’ high bias risk and ‘±’ unclear bias risk.
ACCEL-AMI, adjunctive Cilostazol versus High Maintenance Dose Clopidogrel in patients with AMI; ACCEL-LOADING-ACS, Multicentre
Randomised Trial Evaluating Efficacy of Cilostazol on Platelet Aggregation, Inflammation and Myonecrosis in ACS Patients;
ACCEL-POLYMORPHISM, Cytochrome 2C19 Polymorphism and Response to Adjunctive Cilostazol versus High Maintenance-Dose
Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention; ACCEL-PPI, Pharmacodynamics Effects of Adding Cilostazol versus
Double-dose Clopidogrel in Patients with Acute Myocardial Infarction During Proton Pump Inhibitor Co-administration; ACCEL-RESISTANCE,
Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients with Clopidogrel Resistance; ACS, acute coronary syndrome;
CILON-T, Influence of Cilostazol-based Triple Antiplatelet Therapy on Ischaemic Complication After Drug-eluting Stent Implantation; HD,
high-dose clopidogrel (150 mg); HOST-ASSURE, Harmonising Optimal Strategy for Treatment of Coronary Artery Stenosis—Safety and
Effectiveness of Drug-Eluting Stents and Antiplatelet Regimen; LTA, light transmittance aggregometry; MI, myocardial infarction; NR, not
reported; PIANO-2 CKD, Platelet Reactivity in Patients with Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared with a
High-Maintenance Dose of Clopidogrel; SD, Standard-dose clopidogrel (75 mg).
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Coronary artery diseaseTable 3 Baseline characteristics of included trials for cardiovascular outcomes
Trial Year N Comparison
Follow-up
(months)
Mean
age
(years)
DM
(%) Stent type
DES
(%)
ABCD
46 2014 630 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
12 65 31 BES 100
ACCEL-AMI
29 2010 90 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
1 62 21 PES>SES>ZES 100
ACCEL-
LOADING-
ACS
30
2012 218 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
1 63 23 DES, BMS 95
ACCEL-
RESISTANCE
33
2009 60 Aspirin/clopidogrel/cilostazol
vs aspirin/high-dose
clopidogrel
1 63 23 DES 100
Ahn CM et al
47 2011 130 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
24 64 22 SES 100
Chen YD et al
48 2006 120 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
9 58 30 BMS 0
CIDES
49 2008 280 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
6 62 100 PES, SES 100
CILON-T
34 2011 960 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
6 64 34 PES, ZES 100
CLEAR
50 2011 120 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
6 66 42 SES>ZES>PES>EES 100
CREST
51 2005 705 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
6 60 26 BMS 0
DECLARE-
DIABETES
52 53
2008/
2010
450 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
24 61 100 PES, SES 100
DECLARE-
LONG
53 54
2007/
2010
450 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
24 61 33 PES, SES 100
DECLARE-
LONG II
55
2011 499 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
12 62 35 ZES 100
Gao et al
35 2013 428 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
12 56 18 SES>PES 100
Guan et al
36 2012 840 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
1 60 NR DES 100
Han et al
56 2009 1212 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
12 60 22 BMS, DES 52
Han et al
57 2006 120 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
3 61 23 BMS, DES 43
HOST-
ASSURE
37
2013 3755 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
1 63 32 ZES-R>EES-PtCr 100
Hu et al
58 2013 146 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
12 63 NR NR NR
Jin et al
39 2012 60 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
1 62 45 DES 100
Kim et al
59 2008 109 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
6 68 29 PES>SES 100
Kim et al
41 2007 60 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
1 63 29 SES>PES>others 100
Kum et al
42 2009 603 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
6 62 26 DES 100
Lee et al
60 2007 20 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
1 56 25 NR 100
LONG-
DES-II
61 62
2007 500 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
9 61 33 PES, SES 100
Lu et al
63 2006 120 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
6–9 71 NR BMS 0
Lu et al
64 2007 402 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
6 61 44 BMS, DES 85
Continued
6 Bangalore S, Singh A, Toklu B, et al. Open Heart 2014;1:e000068. doi:10.1136/openhrt-2014-000068
Open Heart(IRR=0.64; 95% CI 0.55 to 0.75) when compared with
DAPT alone (ﬁgure 3A). There was low heterogeneity in
the analysis and no evidence for signiﬁcant publication
bias.
Secondary outcomes
TAPT was associated with similar IRR for death
(IRR=0.79; 95% CI 0.58 to 1.09) (ﬁgure 3B), cardiovas-
cular death (IRR=0.74; 95% CI 0.42 to 1.30) and MI
(IRR=0.85; 95% CI 0.63 to 1.14) (ﬁgure 3C) for the
overall cohort. The IRR was independent of stent type as
TAPT showed beneﬁt regardless whether BMS and DES
was used (stent type, Pinteraction >0.05). In the overall
cohort, TAPT was associated with a 43% reduction in the
risk of TLR (IRR=0.57; 95% CI 0.44 to 0.73) (ﬁgure 3D)
and a 31% reduction in the risk of TVR (IRR=0.69; 95%
CI 0.59 to 0.81) (ﬁgure 3E) compared with DAPT. TAPT
efﬁcacy for reducing TLR and TVR was present even
when the analyses were restricted to studies using DES.
In DES-treated patients, TAPT resulted in a 43% reduc-
tion in TLR (IRR=0.57; 95% CI 0.44 to 0.74) and a 35%
reduction in TVR (IRR=0.65; 95% CI 0.54 to 0.79) with
TAPT compared with DAPT.
TAPT was associated with signiﬁcantly lower stent
thrombosis rate when compared with DAPT (IRR=0.63;
95% CI 0.40 to 0.98) (ﬁgure 3F). There was no hetero-
geneity (0%) in all of the above analyses and no evi-
dence for signiﬁcant publication bias.
Safety outcomes
TAPT was associated with a numerically increased risk of
major (IRR=1.24; 95% CI 0.79 to 1.92) (ﬁgure 4A),
minor (IRR=1.37; 95% CI 0.88 to 2.14) (ﬁgure 4B), or
any bleeding (IRR=1.26; 95% CI 0.99 to 1.61) (ﬁgure
4C) compared with DAPT, although these were not statis-
tically signiﬁcant. TAPT was also associated with a 59%
increase in drug discontinuation due to adverse events
(IRR=1.59; 95% CI 1.32 to 1.91) (ﬁgure 4D) when com-
pared with DAPT. The most commonly listed causes for
drug discontinuation were headache, skin rash and palpi-
tations/tachycardia. There was no-to-modest (for drug
discontinuation outcomes) heterogeneity in all of the
above analyses and no evidence for signiﬁcant publica-
tion bias.
Table 3 Continued
Trial Year N Comparison
Follow-up
(months)
Mean
age
(years)
DM
(%) Stent type
DES
(%)
Min et al
10 2007 59 Aspirin/clopidogrel or
ticlopidine/cilostazol vs
aspirin/clopidogrel or
ticlopidine
6 62 26 BMS 0
OPTIMUS-2
6 2008 50 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
1 64 100 NR 100
Shen et al
65 2010 160 Aspirin/Clopidogrel/
Cilostazol vs Aspirin/
Clopidogrel
12 69 100 DES 100
Suh et al
66 2009 143 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
25 62 100 PES>SES 100
Wang et al
67 2005 193 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
12 62 28 BMS 0
Wang et al
68 2010 164 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
12 68 NR BMS, DES NR
Zang et al
69 2008 263 Aspirin/clopidogrel/cilostazol
vs aspirin/clopidogrel
12 59 100 BMS, DES 53
ABCD, Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients with Long or Multivessel Coronary Artery Disease
underwent Biolimus-Eluting Stent Implantation; ACS, acute coronary syndrome; AMI, acute myocardial infarction; BES, biolimus-eluting stent;
BMS, bare metal stent; CIDES, comparison of cilostazol versus clopidogrel after drug-eluting stenting in diabetic patients; CILON-T, Influence
of Cilostazol-based Triple Antiplatelet Therapy on Ischaemic Complication After Drug-eluting Stent Implantation; CLEAR, The Cilostazol
Administration Before Percutaneous Coronary Intervention for Reduction of Periprocedural Myonecrosis Trial; CREST, Coronary Stent
Restenosis in Patients Treated with Cilostazol; DECLARE-LONG II: Triple Antiplatelet Therapy With Dual Antiplatelet Therapy to Reduce
Restenosis After Drug-Eluting Stent Implantation in Long Coronary Lesions; DECLARE-DIABETES, A Randomised Comparison of Triple
Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients; DECLARE-LONG, Drug-Eluting
Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions; DES, drug-eluting stent; DM,
diabetes mellitus; EES, everolimus-eluting stent; EES-PtCr, everolimus-eluting platinum-chromium alloy stent; LONG-DES, Sirolimus-Eluting
Stent Versus Paclitaxel-Eluting Stent for Patients With Long Coronary Artery Disease; OPTIMUS-2, Impact of Cilostazol on Platelet Function
Profiles in Patients with Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy; PES, Paclitaxel-eluting stent; SES,
Sirolimus-eluting stent; ZES, Zotarolimus-eluting stent; ZES-R, Zotarolimus-eluting Resolute stent.
Other trial expansions as in tables 1 and 2.
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Coronary artery diseaseDISCUSSION
In patients undergoing PCI, TAPT using cilostazol
results in signiﬁcant decrease in platelet reactivity and
reduced risk of HTPR. TAPT resulted in signiﬁcantly
lower mean PRU, greater platelet inhibition and
reduced risk of HTPR in the setting of DAPT with both
standard-dose and high-dose clopidogrel. In addition,
TAPT was associated with a signiﬁcant reduction in CV
events, including reduction in MACE, driven largely by
signiﬁcant reductions in TLR and TVR. Most import-
antly, there was a signiﬁcant lower stent thrombosis with
TAPT versus DAPT. Moreover, the reduction of resten-
osis with TAPT remained even when the analysis was
restricted to trials using DES. In addition, there was
numerically higher bleeding with TAPT versus DAPT,
although this did not reach statistical signiﬁcant.
Table 4 Inclusion criteria and study quality of included cardiovascular outcomes trials
Trial Cohort Quality of study*
ABCD
46 Patients with long or multivessel disease undergoing PCI ++±
ACCEL-AMI
29 Patients with ACS undergoing PCI +++
ACCEL-LOADING-ACS
30 Patients with non-ST-elevation MI undergoing PCI ±±±
ACCEL-RESISTANCE
33 Patients with high on-treatment platelet reactivity undergoing PCI ++±
Ahn et al
47 Patient with ACS undergoing PCI ±±+
Chen et al
48 Patients with ACS undergoing PCI ±++
CIDES
49 Patients with diabetes undergoing PCI ±±±
CILON-T
34 Patients with angina undergoing PCI ++±
CLEAR
50 Patients with stable angina undergoing PCI ±±±
CREST
51 Patients with ACS/known stenosis undergoing PCI +++
DECLARE-DIABETES
52 Patients with ACS and diabetes undergoing PCI +±±
DECLARE-LONG
54 Patients with ACS and stenosis of long (>25 mm) lesions undergoing PCI +±±
DECLARE-LONG II
55 Patients with ACS/known stenosis of long (>25 mm) lesions undergoing PCI +++
Gao et al
35 Obese patients undergoing PCI ±±±
Guan et al
36 Patients with ACS and high on-treatment platelet reactivity undergoing PCI ±±±
Han et al
56 Patients with ACS undergoing PCI ++±
Han et al
57 Patients with ACS undergoing PCI ±±±
HOST-ASSURE
37 All-comer patients undergoing PCI ±±+
Hu et al
58 Patients with ACS undergoing PCI ±±±
Jin et al
39 Patients undergoing PCI ±++
Kim et al
59 Patients with ACS/known stenosis undergoing PCI ±±±
Kim et al
41 Patients with ST-elevation MI undergoing PCI ±±±
Kum et al
42 Patients with ACS/known stenosis undergoing PCI ±±±
Lee et al
60 Patients undergoing elective PCI +±±
LONG-DES-II
61 Patients with stenosis of long lesions undergoing PCI ++±
Lu et al
70 Patients undergoing PCI ±±+
Lu et al
64 Patients with ADP-induced platelet inhibition rates <30% undergoing PCI +±±
Min et al
10 Patients with ACS/known stenosis undergoing elective PCI ±+±
OPTIMUS-2
6 Patients with diabetes undergone PCI +++
Shen et al
65 Patients with ACS undergoing PCI ±±±
Suh et al
66 Patients with diabetes and chronic total occlusion undergoing PCI ±±±
Wang et al
67 Patients with small vessel stenosis undergoing PCI ±±±
Wang et al
68 Patients with non-ST-elevation MI undergoing PCI ±±±
Zang et al
69 Patients with ACS undergoing PCI ±±±
*Represents risk of bias based on: sequence generation of allocation; allocation concealment and blinding. ‘+’ represents low bias risk, ‘−’
high bias risk and ‘±’ unclear bias risk.
ABCD, Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients with Long or Multivessel Coronary Artery Disease
underwent Biolimus-Eluting Stent Implantation; ACS, acute coronary syndrome; AMI, acute myocardial infarction; BES, biolimus-eluting stent;
BMS, bare metal stent; CIDES, comparison of cilostazol versus clopidogrel after drug-eluting stenting in diabetic patients; CILON-T, Influence
of Cilostazol-based Triple Antiplatelet Therapy on Ischaemic Complication After Drug-eluting Stent Implantation; CLEAR, The Cilostazol
Administration Before Percutaneous Coronary Intervention for Reduction of Periprocedural Myonecrosis Trial; CREST, Coronary Stent
Restenosis in Patients Treated with Cilostazol; DECLARE-LONG II: Triple Antiplatelet Therapy With Dual Antiplatelet Therapy to Reduce
Restenosis After Drug-Eluting Stent Implantation in Long Coronary Lesions; DECLARE-DIABETES, A Randomised Comparison of Triple
Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients; DECLARE-LONG, Drug-Eluting
Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions; DES, drug-eluting stent; DM,
diabetes mellitus; EES, everolimus-eluting stent; EES-PtCr, everolimus-eluting platinum-chromium alloy stent; LONG-DES, Sirolimus-Eluting
Stent Versus Paclitaxel-Eluting Stent for Patients With Long Coronary Artery Disease; OPTIMUS-2, Impact of Cilostazol on Platelet Function
Profiles in Patients with Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy; PES, Paclitaxel-eluting stent; SES,
Sirolimus-eluting stent; ZES, Zotarolimus-eluting stent; ZES-R, Zotarolimus-eluting Resolute stent.
Other trial expansions as in tables 1 and 2.
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Open HeartHowever, there was a signiﬁcant increase in the risk of
drug discontinuation due to adverse effects when com-
pared with DAPT.
Platelet reactivity and outcomes
Prior studies have shown a relationship between
on-treatment platelet reactivity and adverse CV events in
Figure 2 (A) Primary platelet reactivity outcome: difference in platelet reactivity units (PRU) after treatment between triple
antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (B) Secondary platelet reactivity outcome: difference in
percent platelet inhibition after treatment between TAPT versus DAPT. (C) Secondary platelet reactivity outcome: risk of high
on-treatment platelet reactivity (HTPR) after treatment between TAPT versus DAPT.
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Coronary artery diseasepatients undergoing PCI. In an analysis of individual
patient data from six studies with 3059 patients, for every
10 U increase in PRU there was a 4% increase in
primary endpoint rate of death, MI or stent thrombosis
(HR 1.04; 95% CI 1.03 to 1.06; p<0.0001).
17 A recent
consensus statement recommended a cut-off of PRU
>235 U as the threshold for identifying patients with
HTPR who may be at high risk for ischaemic or throm-
botic events following PCI.
13 Patients with HTPR have
been shown to have an increased risk of death (110%
increase), MI (104% increase) and stent thrombosis
(211% increase).
17 18
Although platelet reactivity is a surrogate marker, given
the wide interindividual variability in clopidogrel-
induced platelet inhibition,
1–3 various strategies have
been tested to improve platelet inhibition. These strat-
egies have utilised higher loading and maintenance
doses of clopidogrel, or next-generation P2Y12 inhibitors
such as prasugrel and ticagrelor, which are more potent
that clopidogrel and have a more uniform antiplatelet
effect. Doubling of the clopidogrel dose (150 mg) has
been shown to signiﬁcantly reduce PRU in patients with
HTPR.
19–21 Similarly, data from the next-generation
P2Y12 inhibitors such as prasugrel and ticagrelor have
shown improved platelet reactivity indices when com-
pared with clopidogrel.
22 Although the newer agents pra-
sugrel and ticagrelor reduce MACE in randomised trials,
these agents increase bleeding in patients with PCI and
cost signiﬁcantly more than generic clopidogrel.
23 24
Cilostazol, a phosphodiesterase III inhibitor, exhibits
antiplatelet effects by increasing cAMP within platelets,
and is available as a generic drug. Our results show a sig-
niﬁcant beneﬁt of TAPT with cilostazol in improving
platelet reactivity indices in patients undergoing PCI,
with lower PRU, greater platelet inhibition and a signiﬁ-
cant reduction in the risk of HTPR regardless of compari-
son with either standard-dose or high-dose clopidogrel.
In addition, these results were seen even in comparison
with DAPT using high-dose clopidogrel. Given that
generic clopidogrel is now available, many clinicians opt
to prescribe high-dose clopidogrel to address HTPR in
patients who cannot afford newer antiplatelet agents.
The results of the present study show that TAPT with
cilostazol is superior even to DAPT with high-dose clopi-
dogrel. Despite these promising results, a number of lim-
itations must be acknowledged. Although platelet
reactivity is a risk factor/surrogate marker for adverse CV
events, clinical studies have not yet demonstrated that a
pharmacological treatment strategy based on platelet
reactivity improves outcomes.
20 25 In the ARCTIC trial of
2440 patients randomised to platelet-function monitoring
and drug adjustment group versus conventional strategy
of no monitoring and drug adjustment, there were no dif-
ferences in composite of death, MI, stent thrombosis,
stroke, or urgent revascularisation at 1 year between the
two groups, calling into question the utility of adjusting
therapies based on platelet function monitoring.
25
However, because cilostazol inhibits both platelet acti-
vation and smooth muscle proliferation, it has the poten-
tial to target two dreaded complications of PCI—stent
thrombosis and restenosis. TAPT may reduce MACE by
two or more cellular mechanisms.
8–11 Our study shows
Figure 2 Continued
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Open Heartsigniﬁcant reduction in both stent thrombosis and
restenosis using TAPT with cilostazol, even in patients
treated with DES. This is a potential advantage for this
agent, as no antiplatelet agent, including prasugrel or
ticagrelor, has been shown to have any antirestenosis
property.
Figure 3 (A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet
therapy (TAPT) versus dual antiplatelet therapy (DAPT). (B) Secondary cardiovascular outcome: risk of all-cause mortality
between TAPT versus DAPT. (C) Secondary cardiovascular outcome: risk of myocardial infarction between TAPT versus DAPT.
(D) Secondary cardiovascular outcome: risk of target lesion revascularisation (TLR) between TAPT versus DAPT. (E) Secondary
cardiovascular outcome: risk of target vessel revascularisation (TVR) between TAPT versus DAPT. (F) Secondary cardiovascular
outcome: risk of stent thrombosis between TAPT versus DAPT.
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Coronary artery diseaseTherefore, a strategy of using TAPT with cilostazol has
several advantages: (1) it improves the surrogate outcome
of platelet reactivity relative to DAPT, including high-dose
clopidogrel; (2) the antismooth muscle proliferative prop-
erties of cilostazol may make it an excellent agent to
prevent restenosis resulting in reduced TVR even in
patients treated with a DES; (3) the improvement in
platelet reactivity indices translate into signiﬁcant reduc-
tion in stent thrombosis and (4) the medication is avail-
able generically and is therefore less expensive than newer
antiplatelet therapy. Thus, when used following PCI,
TAPT with cilostazol has the potential to be a cost-effective
therapy to improve clinical outcomes by reducing throm-
botic events and restenosis. The results of this study
Figure 3 Continued
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Open Hearttherefore call for a randomised trial comparing a strategy
of TAPT with DAPTusing newer antiplatelet agents.
Our results differ from the studies of Jang et al
26 and
Sakurai et al
27 in that these studies did not evaluate
platelet reactivity outcomes and had far fewer trials
than the current analysis. In our analysis, TAPT was
associated with signiﬁcant increase in drug discontinu-
ation. The most commonly listed causes for drug dis-
continuation were headache, skin rash and
palpitations/tachycardia. Sakurai et al
27 similarly found
as i g n i ﬁcant increase in rash and gastrointestinal side
effects with TAPT.
Figure 3 Continued
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As in other meta-analyses without individual patient
data, we were unable to adjust for dosages of medication
used or with compliance with assigned therapies. Given
heterogeneity in the study protocols, clinically relevant
differences could have been missed and are best
assessed in a meta-analysis of individual patient data.
Stroke would have been interesting to examine, as there
is some evidence that cilostazol reduces stroke.
28 All of
the trials did not report all of the outcomes. The
Figure 4 (A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy
(DAPT). (B) Safety outcome: risk of minor bleeding between TAPT versus DAPT. (C) Safety outcome: risk of any bleeding
between TAPT versus DAPT. (D) Safety outcome: risk of drug discontinuation due to adverse effects between TAPT versus
DAPT.
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Open Heartsubgroup analyses might suffer from multiple testing. In
addition, the results need to be conﬁrmed in an ethnic-
ally diverse population, as most of the trials were done
in Asian populations. However, the CREST and the
OPTIMUS-2 trials, performed mainly in a non-Asian
population, showed similar efﬁcacy of cilostazol when
compared with controls. The individual trials did not
provide sufﬁcient data to stratify analyses by early versus
newer generation DES.
Conclusions
In patients undergoing PCI, TAPT with cilostazol is
associated with signiﬁcantly improved platelet reactivity
indices, even when compared with DAPT with high-
Figure 4 Continued
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Coronary artery diseasedose clopidogrel, and is associated with signiﬁcant
reduction in CV events, including reduction in BMS
and DES restenosis and stent thrombosis. The dual
properties of antiplatelet and antiproliferative action,
the availability as a generic medication combined with
the above data makes TAPT with aspirin, clopidogrel
and cilostazol an attractive and strong competitor for
newer antiplatelet regimens and should be evaluated in
future trials.
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